FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OIVID APPROVAL										
OMB Number:	3235-0287									
Estimated average hu	rden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rueckert William Dodge</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol MEI Pharma, Inc. [MEIP]										tionship o all applica Director	,		on(s) to Issu 10% Ow		
(Last)	(F I PHARMA		3. Date of Earliest Transaction (Month/Day/Year) 07/15/2013										Officer ( below)	give title		Other (s below)	pecify			
11975 EL CAMINO REAL, SUITE 101					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)	EGO C	O CA 92130												X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			. Transactio Date Month/Day/	Execution Date,		,	Code (Instr.   5)				4 and Securitie Beneficia Owned F		s Form		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	V Amoun		t (A) or Price			Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, Transaction of			tive ities red sed	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amou Securities Underly Derivative Securit (Instr. 3 and 4)					derlying curity	ing Derivative		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exe	e rcisable	Expi Date	ration	Title	Amour or Number of Shares	er						
Option to purchase shares of common stock	\$7.43	07/15/2013		A		6,730			(1)	07/1	5/2018	Common Stock par value \$0.00000002	6,730	)	\$0	18,924	(2)	D		

## Explanation of Responses:

- 1. One-third of the options will vest on July 15, 2014; the remaining two-thirds of the options will vest in equal monthly installments over the following twenty-four months
- 2. The total number of derivative securities reported in column 9 includes previously awarded options, which were subject to the effect of a 1 for 6 reverse stock split, which was effective on December 18, 2012

<u>/s/ William D. Rueckert</u> <u>07/17/2013</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.